Salivary HLA-DQA1*05 Genotyping and Anti-TNF Treatment Outcomes in Inflammatory Bowel Disease: An Ambispective Cohort Study with Long-Term Follow-Up
Background/Objectives: HLA-DQA1*05 carriage has been associated with immunogenicity to anti-TNF agents in inflammatory bowel disease (IBD), but real-world data are inconsistent. We assessed whether carriage, determined by salivary genotyping, was associated with anti-TNF effectiveness, persistence and safety. Ambispective here denotes prospective ascertainment of the exposure combined with retrospective capture of outcomes. Methods: This was a single-centre ambispective cohort study of 170 adults with IBD treated with infliximab or adalimumab as their first biologic. HLA-DQA1*05 was genotyped prospectively from saliva (July 2024–April 2025); outcomes were retrieved retrospectively. Primary non-response (PNR), secondary loss of response (SLOR), treatment persistence and adverse events were compared by genotype using Kaplan–Meier and multivariable Cox analyses. Results: Of 167 patients with a conclusive genotype, 74 (44.3%) were carriers; median treatment exposure was 78.5 months. PNR occurred in 12.2% of carriers and 7.5% of non-carriers (odds ratio [OR] 1.70, 95% confidence interval [CI] 0.60–4.81), and SLOR in 53.8% and 47.7% of initial responders (OR 1.28, 95% CI 0.67–2.44). Carriage was not associated with time to SLOR (adjusted hazard ratio [HR] 1.76, 95% CI 0.97–3.21) or with all-cause discontinuation (adjusted HR 0.98, 95% CI 0.62–1.55). Conclusions: In this selected, real-world cohort with long-term follow-up, HLA-DQA1*05 carriage determined in saliva was not associated with anti-TNF failure or treatment persistence, although clinically relevant effects are not excluded. Establishing the clinical utility of HLA-DQA1*05 testing will require prospective genotyping before treatment, with systematic immunogenicity assessment.
Authors
- Cristina Mira
- Lucía Madero-Velázquez
- Ana Gutiérrez (ORCID: https://orcid.org/0000-0002-8823-9029)
- V Ictor Moreno-Torres' (ORCID: https://orcid.org/0000-0002-9798-4514)
- Belén Herreros
- Roser Muñoz (ORCID: https://orcid.org/0000-0002-8833-5424)
- O. Belén‐Galipienso (ORCID: https://orcid.org/0000-0001-9105-831X)
- Isabel García-García
- Antonio García-Trueba
Institutions
- Instituto de Salud Carlos III (ES)
- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (ES)
- Hospital General Universitario de Alicante Doctor Balmis (ES)
- Instituto de Investigación Sanitaria y Biomédica de Alicante (ISABIAL) (ES)
Publication Details
- Journal
- Journal of Clinical Medicine
- Published
- 2026-11-19
- DOI
- https://doi.org/10.3390/jcm15229064
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 0.00